Trial Profile
Pilot Trial of Humanized 3S193 Monoclonal Antibody (hu3S193) in Presurgical Patients With Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3S193 (Primary) ; Monoclonal antibody 3S193 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 20 Jul 2021 Status changed from completed to discontinued.
- 15 Oct 2014 New trial record